Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MMP7 | P09237 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131956 | 0.92 | FKBP1A (0.47) | RAB9ANPC1FKBP1AALDH1A1PKM | |
| SCHEMBL5128422 | 0.91 | ALDH1A1 (0.46) | RAB9ANPC1FKBP1AALDH1A1PKM | |
| SCHEMBL2569189 | 0.85 | FKBP1A (0.51) | RAB9ANPC1FKBP1AALDH1A1PKM | |
| SCHEMBL5128989 | 0.84 | RAB9A (0.46) | RAB9ANPC1FKBP1AALDH1A1PKM | |
| SCHEMBL5125464 | 0.82 | PKLR (0.47) | FKBP1AALDH1A1PKMPAX8 | |
| SCHEMBL5132136 | 0.81 | CYP46A1 (0.42) | RAB9ANPC1FKBP1A | |
| SCHEMBL493175 | 0.81 | RAB9A (0.58) | RAB9ANPC1FKBP1AALDH1A1MMP1 | |
| SCHEMBL2566158 | 0.81 | NPC1 (0.49) | RAB9ANPC1FKBP1AALDH1A1PKM | |
| SCHEMBL5132117 | 0.81 | CYP46A1 (0.44) | RAB9ANPC1FKBP1AALDH1A1 | |
| SCHEMBL5125427 | 0.80 | CYP46A1 (0.42) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | claimed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | RAB9A 2479/4885NPC1 1989/4885FKBP1A 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.